Chagas cardiomyopathy, caused by the parasite Trypanosoma cruzi, is a significant cause of cardiac pathology worldwide. Though most frequently observed in Latin America, Chagas disease is present in the United States and should be considered in patients with heart block or other cardiac abnormalities and previous travel to or residence in endemic areas. Here we describe a new diagnosis of Chagas cardiomyopathy in a patient residing in Virginia with a previous residence in Mexico.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438999 | PMC |
| http://dx.doi.org/10.7759/cureus.42158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ninoa Strain Modifies the Expression of microRNAs in Cardiac Tissue and Plasma During Chagas Disease Infection.
Pathogens
December 2024
Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez (INCICH), Mexico City 14080, Mexico.
Chronic chagasic cardiomyopathy is the most severe clinical manifestation of Chagas disease, which affects approximately seven million people worldwide. Latin American countries bear the highest burden, with the greatest morbidity and mortality rates. Currently, diagnostic methods do not provide information on the risk of progression to severe stages of the disease.
View Article and Find Full Text PDFImmunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate.
PLoS Pathog
December 2024
Texas Children's Hospital Center for Vaccine Development, Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Trypanosoma cruzi is a protozoan parasite that causes Chagas disease. Globally 6 to 7 million people are infected by this parasite of which 20-30% will progress to develop Chronic Chagasic Cardiomyopathy (CCC). Despite its high disease burden, no clinically approved vaccine exists for the prevention or treatment of CCC.
View Article and Find Full Text PDFResolution of ventricular tachycardia and cardiac inflammation following treatment in chronic Chagas disease.
HeartRhythm Case Rep
November 2024
UCLA Cardiac Arrhythmia Center, UCLA Medical Center, Los Angeles, CA.
Impact of non-ionic surfactants on release kinetics, toxicity and colloidal characteristics of benznidazole self-emulsifying delivery system evidenced by flow field-flow fractionation.
J Chromatogr A
January 2025
Laboratory of Pharmaceutics and Nanotechnology (LDGNano), School of Pharmacy, Federal University of Ouro Preto, Minas Gerais 35400-000, Brazil. Electronic address:
Chagas disease is the major cause of death by cardiomyopathy in Latin America. Benznidazole (BZN) tablets are the standard of care for Chagas disease, and recently, self-emulsifying systems (SEDDS) have shown promising efficacy as the BZN delivery system, particularly for pediatric use. However, the comparative effects of surfactants on the physicochemical properties of SEDDS have been poorly investigated to date.
View Article and Find Full Text PDFEnhancing Ventricular Tachycardia Ablation Outcomes: The Impact of Functional Mapping in Chagas Cardiomyopathy.
JACC Clin Electrophysiol
November 2024
Unit of Cardiology and Cardiovascular Surgery, Clinics Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Advanced Arrhythmia Treatment Center, Belo Horizonte, Brazil. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!